Monsanto Tells Bayer to Buzz Off, Flatly Rejecting Their All Cash $62 Billion Bid

Sixty two billion is chicken feed for the bird brains over at Monsanto. Plainly and without equivocation, they rejected the Bayer Aspirin companies repulsive, $62 billion, all cash offer.

With Monsanto under their wings, the Bayer folks might inject their GMO technology into their line of polyurethane foam products, in order to convert ordinary Americans into monsters.

Word on the street is that Monsanto wants more money, a lot more money.

Bayer on Monday made public its offer of $122 a share in cash, or a 37 percent premium. Monsanto shares rose 1.9 percent to $108 at 11:53 a.m. in New York. A representative at Monsanto declined to comment. Reuters reported the Monsanto board’s decision earlier on Tuesday.

Bayer will likely come back with a higher bid, Jonas Oxgaard, an analyst with Sanford C. Bernstein & Co. in New York, said Tuesday in a note, adding that an offer below $135 per share would be “challenging” for Monsanto to agree to.

Shares of MON are higher by 2.5% to $109.